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Abstract
Background: As comparisons of modern medical and surgical second trimester termination of
pregnancy (TOP) are limited, and the optimum method of termination is still debated, an audit of
second trimester TOP was undertaken, with the objective of comparing the outcomes of modern
medical and surgical methods.
Methods: All cases of medical and surgical TOP between the gestations of 13 and 20 weeks from
1st January 2007 to 30th June 2008, among women residing in the local health board district, a
tertiary teaching hospital in an urban setting, were identified by a search of ICD-10 procedure
codes (surgical terminations) and from a ward database (medical terminations). Retrospective
review of case notes was undertaken. A total of 184 cases, 51 medical and 133 surgical TOP, were
identified. Frequency data were compared using Chi-squared or Fischer's Exact tests as appropriate
and continuous data are presented as mean and standard deviation if normally distributed or
median and interquartile range if non-parametric.
Results: Eighty-one percent of surgical terminations occurred between 13 to 16 weeks gestation,
while 74% of medical terminations were performed between 17 to 20 weeks gestation. The earlier
surgical TOP occurred in younger women and were more often indicated for maternal mental
health. Sixteen percent of medical TOP required surgical delivery of the placenta. Evacuation of
retained products was required more often after medical TOP (10%) than after surgical TOP (1%).
Other serious complications were rare.
Conclusion:  Both medical and surgical TOP are safe and effective for second trimester
termination. Medical TOP tend to be performed at later gestations and are associated with a
greater likelihood of manual removal of the placenta and delayed return to theatre for retained
products. This case series does not address long term complications.
Background
Termination of pregnancy (TOP) is the most common
procedure performed worldwide and each year in New
Zealand approximately 18,000 TOPS are performed [1,2].
Both medical and surgical termination techniques have
evolved over the last 30 years, and are continually improv-
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ing with regard to effectiveness, acceptability and rate of
complications [1].
For the past 50 years the procedure has been completed
using surgical approaches, mostly dilatation and evacua-
tion (D&E) of the uterus. However, over the past two dec-
ades the development of medical approaches using
antiprogesteronic agents and prostaglandin analogues has
provided an alternative for women seeking TOP [3]. Med-
ical TOP involves oral mifepristone, a progesterone antag-
onist which sensitises the myometrium to prostaglandin
induced contractions and ripens the cervix, followed by
misoprostol, a synthetic prostaglandin E1 analogue,
orally and/or vaginally, which causes uterine contractions
and cervical dilatation [2,3]. The addition of the proges-
terone antagonist reduces the induction to abortion inter-
val, analgesia required and prostaglandin dose [3,4].
Surgical termination consists of prior dilapan rod inser-
tion and misoprostol priming to dilate and soften the cer-
vix, followed by D&E under local or general anaesthetic
[3]. Dilapan rods are hydrophilic polymer rods which
work by absorbing fluid and slowly expanding, therefore
causing cervical dilatation [4].
Ideally, TOP should be performed in the first trimester as
this is safer and more acceptable. However, for some
women, second trimester TOP is unavoidable; screening
for Trisomy 21 does not occur until late in the 1st trimes-
ter, there may be poor access to services or fear of disclo-
sure of the pregnancy [3,5]. While second trimester TOP
accounts for 10-15% of termination worldwide [6,7], it
accounts for two-thirds of all major termination related
complications [7,8].
Comparisons of modern medical and surgical methods
for second trimester TOP are limited, and the optimum
method of termination is debated. Only one study of
women undergoing second trimester TOP, comparing
D&E to mifepristone and misoprostol, met the criteria for
a Cochrane Review in 2008 [3,9]. This study included
only 18 women and there was no evidence of a difference
in outcomes with the exception of adverse events and
overnight stay, which were more common in the medical
group [9]. Further studies were suggested.
The objective of this study was to audit second trimester
TOP at National Women's Hospital, Auckland, New Zea-
land, over an eighteen month period by retrospective
review of case notes. Specific aims were to compare
patient characteristics and complication rates of modern
medical and surgical TOP methods.
Materials and methods
Cases include all women residing in the Auckland District
Health Board area who underwent modern medical or
surgical second trimester TOP (13 to 20 weeks) at
National Women's Health, Auckland New Zealand, from
January 2007 to June 2008. All medical and surgical sec-
ond trimester TOPs are performed at the ADHB. No other
facilities are licensed to perform second trimester TOP in
the Auckland region. Women who meet the criteria for
TOP between 13 and 20 weeks gestation have a consulta-
tion with a certifying consultant for TOP and are offered
either medical or surgical TOP. The advantages and disad-
vantages of both methods are discussed including the
benefits of detailed post mortems where fetal abnormality
is present. Cases were identified from ICD-10 procedure
codes for surgical TOP and from a database maintained by
the service for medical TOP. Coding data were searched
for presence of any further medical TOPs but no other
cross-verification was possible. Patient characteristics and
clinical details were obtained from the electronic case
notes by retrospective review.
The protocol used for medical TOP was as follows: 600
mg mifepristone orally, admission to gynaecology ward
36-48 hours later, 800 micrograms misoprostol vaginally
then 400 micrograms misoprostol orally at three hourly
intervals, with a maximum of four oral doses. If signifi-
cant bleeding occurred prior to planned admission,
admission occurred at that time and the misoprostol reg-
imen commenced. Manual removal of the placenta was
recommended after delivery if the placenta did not deliver
spontaneously. Pain relief was offered at regular intervals
during the procedure according to a protocol that
included morphine or pethidine given intravenously. In
women with more severe pain a patient controlled anaes-
thesia pump (PCA) was made available that administered
morphine.
The protocol for surgical termination was as follows: dila-
pan rod insertion 12 to 24 hours prior to the procedure,
misoprostol 400 micrograms orally or vaginally one to
three hours before the procedure, followed by D&E [2,3].
During the procedure intravenous fentanyl (maximum
dose of 20 mg) and midazolam (maximum dose 3 mg)
was given and rectal suppositories of paracetamol (1 gm)
and voltaren (75 mg) were given.
The following information was extracted from medical
records: age, parity, ethnicity, history of previous TOP,
previous caesarean section, indication for TOP, contracep-
tion when pregnancy resulted from contraceptive failure,
gestation at TOP, complications and follow up arrange-
ments recorded. Additional information collected for
patients who underwent medical TOP included misopros-
tol dose, time from mifepristone to delivery, time from
admission to delivery, time from delivery of the fetus to
delivery of the placenta, whether manual removal of the
placenta was required, and nights spent in hospital. Addi-
tional information for patients who underwent surgicalReproductive Health 2009, 6:16 http://www.reproductive-health-journal.com/content/6/1/16
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TOP included blood loss, number of dilapan rods, anaes-
thetic method and length of procedure.
The following were regarded as complications of the pro-
cedure:
• haemorrhage requiring transfusion;
￿ infection requiring intravenous antibiotics;
￿ retained products of conception requiring dilatation
and curettage;
￿ laparotomy (any indication including repair of uter-
ine rupture, hysterectomy);
￿ uterine perforation and cervical laceration; and
￿ unscheduled re-admission. Unscheduled re-admis-
sion was defined as a hospital stay of more than three
hours.
Statistical methods
Statistical analyses were performed using STATA9 soft-
ware. Statistical significance was defined as p < 0.05. Fre-
quency data were compared using Chi-squared or
Fischer's Exact tests as appropriate. Continuous data are
presented as mean and standard deviation if normally dis-
tributed or median and interquartile range if non-para-
metric.
Results
A total of 184 terminations of pregnancy, between 1st Jan-
uary 2007 and 30th June 2008 at 13 weeks to 19 weeks
and 6 days gestation, were identified. All case notes were
available for review. Fifty-one were medical TOP and 133
were surgical. Two women had two TOP during the time
period. Both episodes are included in the dataset.
There was a significant difference in gestational age
between the two methods, with 81% of surgical TOP per-
formed between 13 and 16 weeks, and 74% of medical
TOP were performed between 17 and 20 weeks.
Surgical TOP was more common among younger women,
having TOP at earlier gestations, and most commonly for
maternal mental or physical health reasons (table 1).
All ten TOP following intrauterine fetal demise and spon-
taneous rupture of the membranes had medical induction
of labour. Where the indication for termination was
"adjustment disorder and depressed mood following a
diagnosis of a fetal abnormality" medical TOP was the
preferred method.
Overall 30% of women undergoing mid-trimester TOP
had a history of prior TOP, and 10% had two or more
prior TOP. Pregnancy following contraceptive failure
occurred in at least 73 cases (40%). Among the 73 of
women who had conceived following failed contracep-
tion, 27% underwent medical TOP and 44% underwent
surgical TOP.
Data were unavailable for a further 21%. The most com-
mon method of contraception among contraceptive fail-
ures leading to TOP was condom failure when condoms
were used alone (66%), followed by the combined oral
contraceptive pill (COCP) (14%), the emergency contra-
ceptive pill (ECP) (4%), the progesterone only pill (3%),
Depo Provera (2%), condoms in combination with the
COCP (1%), condoms in combination with the ECP (4%)
and unknown in 3%.
Within the medical TOP group seven women (14%)
aborted following mifepristone and the initial vaginal
dose of misoprostol. These included two women who had
spontaneous rupture of membranes (SROM), and one
with intra-uterine fetal demise (IUFD). Two women who
had an IUFD did not require misoprostol. The remaining
women aborted successfully following 1-4 doses of oral
misoprostol. Only 10% of women required 4 oral doses.
Twenty-one (41%) of women were managed as a day case
and a further 43% had one over-night stay. Table 2 reports
on the time involved in medical TOP. The median hospi-
tal stay, from admission for misoprostol to discharge, was
24 hours. The median length of labour was 5.1 hours (3.3-
9.5 interquartile range) among the 70% of women for
whom this data were available. Induction-to-abortion
interval, defined as the time interval from first misopros-
tol administration to delivery of fetus, was 8 hours (5-11
interquartile range). Eight (16%) of women went to oper-
ating theatre for manual removal of the placenta. The time
from delivery to manual removal of the placenta was less
than 5 hours in 6 women and the remaining two were
within 10 hours and included one woman with a partial
delivery of the placenta.
In almost all cases where the number of dilapan rods used
was known, two were inserted into the cervix. Two
women, at 13 and 14 weeks gestation did not have dila-
pan rods inserted prior to D&E. Eighty percent of surgical
TOP were carried out under local anaesthetic with seda-
tion. The mean length of procedure was 8.2 minutes
(standard deviation 2.1), and mean blood loss 199 ml
(standard deviation 97).
A comparison of complications by method is shown in
Table 3 Women undergoing medical TOP were at a signif-
icantly higher risk of requiring evacuation of retained
products of conception (10% among medical TOP com-Reproductive Health 2009, 6:16 http://www.reproductive-health-journal.com/content/6/1/16
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pared to 1% of surgical TOP; p= 0.02). One woman, with
a history of postpartum haemorrhage, in the medical TOP
group, required a three unit blood transfusion for exces-
sive bleeding post delivery.
Sixty-one percent of women had been prescribed contra-
ception or had a plan documented prior to discharge.
Among the 73 who conceived following contraceptive
failure only 8 women (11%) did not have the plan for
contraception recorded in their records.
Discussion
This paper describes the outcomes of 133 surgical and 51
medical TOP between 13 and 20 weeks from January 1
2007 to June 30 2008 at one tertiary institution. Surgical
termination is most often performed at an earlier gesta-
tion, with ninety-nine percent performed before the end
of the 17th week, while medical TOP is almost always per-
formed at or beyond 16 weeks. These differences reflect
the ease and safety of early D&E; and the relative ease and
safety of late medical induction. The decision about the
Table 1: Demographic and clinical details of women undergoing mid-trimester TOP by method of termination
Medical
n = 51
Surgical
n = 133
P
n% n%
Age (yrs)
<20 4 8 32 24
20-24 12 24 37 28
25-29 6 12 22 16
30-34 11 22 16 12
35-39 12 24 16 12
≥40 6 12 10 7 0.04
Median (IQR) 31 (24-38) 24 (20-32) <0.001
Ethnicity
European 19 37 47 35
Maori 4 8 17 13
Pacific 12 24 35 26
Asian 14 27 28 21
Other 2 4 5 4
Unknown 0 1 1 0.9
Parity
Nulliparous 22 43 71 53
Parous 25 49 53 40
Unknown 4 8 9 7 0.5
Previous caesarean section
Yes 7 14 15 11
No 35 69 107 80
Unknown 9 18 11 8 0.2
Previous TOP
No 31 61 88 66
Yes 16 31 36 27
Unknown 4 8 9 7 0.8
Indication for TOP
Maternal mental or physical health 411 80 1332 100
Intrauterine death 5 10 0 0
Spontaneous rupture of membranes 5 10 0 0
Gestation (wks)
13 0 6 5
14 4 8 35 26
15 3 6 31 23
16 6 12 36 27
17 8 16 23 17
18 14 27 1 1
19 14 27 1 1
20 2 4 0 <0.001
Median (IQR) 18 (16-19) 15 (14-16) <0.001
1 Includes two TOP for maternal physical health and 21 TOPs for adjustment disorder with depressed mood following a diagnosis of fetal 
abnormality
2 Includes 114 TOPs for adjustment disorder with depressed mood following a diagnosis of fetal abnormalityReproductive Health 2009, 6:16 http://www.reproductive-health-journal.com/content/6/1/16
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method of second trimester TOP is made jointly between
the women and the medical practitioner. All women are
offered medical TOPs. This study has not explored the rea-
sons for the decision and future assessment of this is
planned. The difference in gestation between the two
techniques makes comparing complications difficult. All
medical TOPS were successful although 16% of cases
required manual removal of the placenta. All other seri-
ous adverse events were comparable between the two
groups, although a study of this size has a small chance of
picking up a difference in rates of rare outcomes.
One explanation for the higher rates of evacuation for
retained products of conception could be the higher ges-
tations in the medical TOP group. Later gestation at the
time of the TOP is associated with an increased risk of
retained products although Autry et al [10] adjusted for
gestation and still found an increase in risk following
medical TOP. The outcomes reported by Autry are not
strictly comparable as the mean gestation for medical
treatment is 20 weeks and the medical method is not
clearly described (a combination of laminaria and miso-
prostol) [10]. Autry also reported that the use of misopr-
ostol was associated with fewer complications (failed
initial procedure and retained products) than laminaria
for medical terminations [10]. The percentage of women
requiring manual removal of placenta following medical
termination of pregnancy in our study (16%), is also high
compared to other studies using similar techniques
[5,11]. Ashok [5] reported 7% requiring manual removal
of placenta, and Goh 10 found an incidence of 5%. Both
of these studies had a significantly larger subject group
than this study, with 999 and 386 subjects respectively.
Only one woman required transfusion following medical
TOP. None of the surgical patients required a blood trans-
fusion which compares favourable with previous studies
on D&E [12]. The large proportion of procedures carried
Table 2: Details of medical terminations (13-19 weeks)
Medical TOP
n = 51
nI Q R e
Median dose of misoprostol given (total) 20 - 4
Median hours from mifipristone dose to delivery of fetus 53 49-56
Median hours from misoprostol to delivery of fetus 8 5-11
Median hours from admission to discharge 24 10-30
Median hours from delivery of fetus to delivery of placenta 0.4 0-2
Data are median (interquartile range)
Table 3: Complications following termination of pregnancy (13-19 weeks) by method of termination
Medical
n = 51
Surgical
n = 1331
P
n% n%
Nights in hospital not including readmissions
0 21 41 -
1 22 43
2 61 2
3 12
5 12
Manual Removal of placenta2,3 81 6 -
Complications
Readmission > 3 hours 3 6 6 4 0.7
Evacuation for retained products of conception2 5 10 2 1 0.02
Endometritis requiring intravenous antibiotics 1 2 3 2 1.0
Blood transfusion 12 00 0 . 3
1 no surgical cases were admitted
2 manual removal of placenta and evacuation for retained products of conception were not mutually exclusive
3 there was one case of partial expulsion of the placenta but required manual removal at 17 hours.Reproductive Health 2009, 6:16 http://www.reproductive-health-journal.com/content/6/1/16
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out under LA (80%) may explain this outcome, as use of
GA has been associated with increased blood loss [12].
These findings are consistent with previous reported series
[5,10] and the one small published randomised control-
led trial [5]. Even in the larger series, there is no evidence
of increased complications among either surgical or med-
ical TOP other than the increased rate of evacuation for
retained products following medical TOP.
Other findings from this report have highlighted some
deficiencies in recording contraception at the time of dis-
charge. It is unknown if this reflects poor record keeping
and this will be addressed by the service in the future. For
those women who had failed contraception leading to the
TOP, only 11% did not have a contraceptive plan.
There are several limitations to this study. Firstly, this is a
retrospective review of complications. Ideally, clinical
data collection should be prospective. Secondly, ascer-
tainment of complications may not have been complete
in this study as identification of major complications was
reliant on re-referral or re-admission to the hospital were
the procedure was performed. Thirdly, the study groups
are not strictly comparable because of the difference in
gestation and indications. Finally, the study does not
address long term adverse effects such as increased risk of
preterm birth and sub-fertility from either second trimes-
ter medical or surgical TOPs.
Previous studies would suggest that even at the upper lim-
its of mid-trimester, D&E is associated with fewer compli-
cations, shorter duration, and less pain and emotional
distress [5,9,11]. To undertake D&E safely and effectively
in the middle trimester of pregnancy, specialist training
and an adequate caseload are required, and the Royal Col-
lege of Obstetricians and Gynaecologists (RCOG) and the
World Health Organisation (WHO) advise inexperienced
professionals to use medical methods [13,14]. What is not
clear from the published literature is whether there is any
long term risk resulting from late TOP. This question
might be addressed in a randomised trial, though in the
USA poor recruitment made such a study unfeasible [9].
Our preliminary audit raises a number of questions
regarding the outcomes and the optimal method for sec-
ond trimester TOP. Further research should consider an
experimental study design such as a randomised control-
led trial comparing D&E with mifepristone and misopros-
tol in the 15th to 18th weeks of pregnancy for TOP
including an assessment of patient satisfaction and long
term outcomes. A case-control study might also be of
value in addressing some of the less common adverse out-
comes.
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